FLT3 and neoplasm: FLT-3 ligand-induced tumor mice resulted in an increase in all splenic cDC resident and migratory subsets negative for CXCR4, with 30.4% of CXCR4− cDCs being CD8α+, 59.5% were CD11b+, and 42.2% were CD103+ (Fig. 4D).